Fluid Test Markers in Patients with Soft Tissue Sarcoma
Studies lung fluid samples from soft tissue sarcoma patients to look for markers of spread.
Plain-language title generated from the registry record
Registry title: BAL Fluid Biomarkers in Sarcoma
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with soft tissue sarcoma who are having a lung lesion removed as part of their usual care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Soft tissue sarcoma, with a lung lesion that is being removed by surgery as part of standard care.
Main reasons for not taking part
- History of another invasive cancer, except non-melanoma skin cancer or tumors treated to remove all disease with no sign of disease for 2 years or more
- Cannot understand or sign the written consent form
Read by machine on 12 November 2026.
Where in Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health NetworkToronto, CanadaContact: David ShultzTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06815666
- Record updated
- 4 March 2026
- Original description
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.Read full original descriptionShow less
Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Inclusion: Age ≥ 18 years; Ability to understand and willingness to sign a written informed consent document; Diagnosed with soft tissue sarcoma; Undergoing resection of lung lesion as part of standard care.
Exclusion: History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years.